{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eosinophilia&page=4", "query": { "condition": "Eosinophilia", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 235, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eosinophilia&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eosinophilia&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T00:58:56.033Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03656380", "title": "Mepo for Eosinophilic Esophagitis (EoE) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EoE", "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Mepolizumab 300 mg", "type": "DRUG" }, { "name": "Mepolizumab 100 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 66, "start_date": "2019-03-20", "completion_date": "2022-12-09", "has_results": true, "last_update_posted_date": "2023-08-23", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 4, "location_summary": "Chicago, Illinois • Minneapolis, Minnesota • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656380" }, { "nct_id": "NCT00109707", "title": "A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myelogenous Leukemia", "Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)", "Hypereosinophilic Syndrome", "Systemic Mastocytosis" ], "interventions": [ { "name": "Nilotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 507, "start_date": "2005-04", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2021-06-29", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 24, "location_summary": "Duarte, California • Stanford, California • Aurora, Colorado + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109707" }, { "nct_id": "NCT02453126", "title": "Fibrostenotic Eosinophilic Esophagitis: Assessment Tools", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "5 Years to 18 Years" }, "enrollment_count": 250, "start_date": "2014-12", "completion_date": "2024-06", "has_results": false, "last_update_posted_date": "2024-02-05", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453126" }, { "nct_id": "NCT01227278", "title": "A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Benralizumab 100 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 421, "start_date": "2010-11", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2016-10-05", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 9, "location_summary": "Los Angeles, California • Marietta, Georgia • Normal, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Normal", "state": "Illinois" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01227278" }, { "nct_id": "NCT05152563", "title": "A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Gastritis", "Eosinophilic Duodenitis" ], "interventions": [ { "name": "AK002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allakos Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2021-12", "completion_date": "2022-01-20", "has_results": false, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 70 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05152563" }, { "nct_id": "NCT04046939", "title": "Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Eosinophilic Asthma", "Asthma" ], "interventions": [ { "name": "Dexpramipexole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Knopp Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 534, "start_date": "2019-08-15", "completion_date": "2021-03-02", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 36, "location_summary": "Los Angeles, California • Mission Viejo, California • Westminster, California + 30 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Westminster", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04046939" }, { "nct_id": "NCT01022970", "title": "Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "QAX576 placebo", "type": "DRUG" }, { "name": "QAX576", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 25, "start_date": "2009-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2021-03-11", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 5, "location_summary": "Stanford, California • Chicago, Illinois • Minneota, Minnesota + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneota", "state": "Minnesota" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Springfield", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01022970" }, { "nct_id": "NCT06750289", "title": "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Asthma" ], "interventions": [ { "name": "ICS-LABA", "type": "COMBINATION_PRODUCT" }, { "name": "benralizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo for Benralizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 400, "start_date": "2025-03-28", "completion_date": "2028-11-03", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 34, "location_summary": "Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Inglewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06750289" }, { "nct_id": "NCT02605837", "title": "A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Oral Budesonide Suspension (OBS)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "11 Years to 55 Years" }, "enrollment_count": 318, "start_date": "2015-12-07", "completion_date": "2019-02-15", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 77, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605837" }, { "nct_id": "NCT04943744", "title": "Gastrointestinal STRING Test With Oral Immunotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Eosinophilic Disorder", "Food Allergy" ], "interventions": [ { "name": "Entero-tracker", "type": "DEVICE" }, { "name": "omalizumab", "type": "BIOLOGICAL" }, { "name": "dupliumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DEVICE", "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "5 Years to 55 Years" }, "enrollment_count": 13, "start_date": "2021-05-17", "completion_date": "2024-05-17", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-04T00:58:56.033Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04943744" } ] }